World's Best Scientists 2026 revealed!
Pier Luigi Zinzani

Pier Luigi Zinzani

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
124
Citations
65521
World Ranking
3193
National Ranking
90

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Pier Luigi Zinzani is affiliated with the University of Bologna in Italy. Their research primarily spans the field of Medicine with a significant focus on hematological diseases and oncology. The scientist has contributed extensively to various subfields including Pathology and Forensic Medicine, Oncology, Genetics, Immunology, and Dermatology.

Their principal research topics include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Cutaneous lymphoproliferative disorders research
  • Viral-associated cancers and disorders
  • Cancer Immunotherapy and Biomarkers
  • CNS Lymphoma Diagnosis and Treatment

Zinzani has published in several frequently appearing journals, notably:

  • Blood
  • Hematological Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere

Some of their recent papers include:

  • "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee," 2022, Blood
  • "Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial," 2021, Nature Medicine
  • "Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial," 2021, The Lancet Oncology
  • "Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations," 2023, Blood
  • "Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study," 2021, The Lancet Oncology

Frequent co-authors working alongside Zinzani are:

  • Beatrice Casadei
  • Alessandro Broccoli
  • Lisa Argnani
  • Wojciech Jurczak
  • Paolo Corradini

Best Publications

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell

  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

    Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink

  • Follicular lymphoma international prognostic index.

    Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White

  • PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

    Ajay K. Gopal;Ajay K. Gopal;Brad S. Kahl;Sven de Vos;Nina D. Wagner-Johnston

  • Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

    Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

    Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • ALK+ Lymphoma: Clinico-Pathological Findings and Outcome

    Brunangelo Falini;Stefano Pileri;Pier Luigi Zinzani;Antonino Carbone

  • Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

    S A Pileri;S Ascani;M C Cox;C Campidelli

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    Philippe Armand;Margaret A. Shipp;Vincent Ribrag;Jean Marie Michot

  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    Owen A. O'Connor;Barbara Pro;Lauren Pinter-Brown;Nancy Bartlett

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

    Emanuele Zucca;Annarita Conconi;Ennio Pedrinis;Sergio Cortelazzo

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    H Miles Prince;H Miles Prince;Youn H Kim;Steven M Horwitz;Reinhard Dummer

  • T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication.

    Hongxiang Liu;Hongtao Ye;Agnes RuskoneFourmestraux;Daphne De Jong

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

    Simonetta Viviani;Pier Luigi Zinzani;Alessandro Rambaldi;Ercole Brusamolino

Frequent Co-Authors

Stefano Pileri
Stefano Pileri European Institute of Oncology
Sante Tura
Sante Tura University of Bologna
Michele Baccarani
Michele Baccarani University of Bologna
Umberto Vitolo
Umberto Vitolo University of Turin
Stefano Fanti
Stefano Fanti University of Bologna
Armando Santoro
Armando Santoro Humanitas University
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Philippe Armand
Philippe Armand Harvard University
Brunangelo Falini
Brunangelo Falini University of Perugia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring healthcare careers in the USA doesn’t always mean pursuing a traditional MD path. Many students are turning to flexible online nursing degrees to broaden their options and enter the medical field efficiently. For registered nurses who want to advance without the challenges of in-person requirements, there are rn bsn online programs no clinicals that emphasize theory, leadership, and evidence-based practice rather than hands-on clinical hours.

For aspiring nurse leaders and practitioners seeking to further their education, you’ll find accelerated dnp programs online that allow you to complete advanced degrees in a shorter timeframe. If ease of coursework and program flexibility are priorities, researching the easiest dnp program reddit discussions and guides can help you find a suitable program matched to your needs.

Fast entry into the nursing workforce is also possible through lpn online programs. These options provide foundational nursing knowledge and skills, making them popular for those looking to start working quickly or build toward future degrees.

Best Scientists Citing Pier Luigi Zinzani

Trending Scientists